chevron_leftBack
As of 24 April 2025, Gemina Laboratories Ltd. has a market cap of $54.14M USD, ranking #24253 globally and #715 in Canada. It ranks #2454 in the Healthcare sector, and #782 in the Biotechnology industry.
Key Stats
Market Cap
$54.14MUSD
74.97M CAD
Enterprise Value
$55.16MUSD
76.39M CAD
EBITDA (TTM)
-$2.55MUSD
-3.54M CAD
Net Income (TTM)
-$2.47MUSD
-3.41M CAD
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Biotechnology
CEO
Brian Firth
open_in_new
Employees
6
Founded
2017
Website
geminalabs.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| 0% | -13% | -7.4% | 82% | 213% | 122% |
Upcoming Earnings
Earnings Date
Fri, May 30
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
GLAB
Gemina Laboratories Ltd
ISIN: CA3686501071
Shares Out.:
Shares Outstanding:
74.864M1
Shares Float:
41.962M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
1.00 CAD | |
|
GLAB
Gemina Laboratories Ltd
ISIN: CA3686501071
|
1.20 CAD | |
|
GLABF
Gemina Laboratories Ltd
ISIN: CA3686501071
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
0.5305 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Gemina Laboratories Ltd.
Gemina Laboratories Ltd., a biotechnology company, engages in the research, development, and commercialization of in-vitro diagnostics in Canada. The company develops LEGIO X COVID-19, a COVID-19 rapid antigen test; and LEGIO X Influenza AB, an influenza AB multiplex lateral flow test. It is developing respiratory syncytial virus and tuberculosis. Gemina Laboratories Ltd. was incorporated in 2017 and is headquartered in Burnaby, Canada.
